Market Overview

UPDATE: Benchmark Downgrades BioClinica to Hold Following Sale Agreement


Benchmark downgraded BioClinica, Inc (NASDAQ: BIOC) from Buy to Hold and maintained a $7.25 price target.

Benchmark said, "BioClinica announced it has entered into a definitive agreement with the private equity firm, JLL Partners, to acquire BioClinica for $7.25 per share. This reflects 1.6x our forecast 2012 revenue of $77.4 million and is a 23% premium to the prior 90-day trading average. … Based on the current price of $7.21, we feel shares now reflect our anticipation this transaction will shortly be completed. Our downgrade to Hold reflects the limited upside to the agreed $7.25 transaction price."

BioClinica closed at $7.21 on Wednesday.

Latest Ratings for BIOC

Mar 2019Maxim GroupInitiates Coverage OnBuy
Jun 2017Chardan CapitalInitiates Coverage OnBuy
Nov 2016Feltl & Co.UpgradesHoldBuy

View More Analyst Ratings for BIOC
View the Latest Analyst Ratings


Related Articles (BIOC)

View Comments and Join the Discussion!

Posted-In: BenchmarkAnalyst Color Downgrades Analyst Ratings

Latest Ratings

RIGRF LaffertyMaintains5.0
NOVRF LaffertyMaintains13.0
WSCDA DavidsonMaintains19.0
ITTDA DavidsonReiterates70.0
NOWGoldman SachsMaintains376.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at